An observational study in Cardiovascular Diseases, sponsored by Translumina Therapeutics Pvt Ltd.. Recruiting at 32 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Translumina Therapeutics Pvt Ltd. · Observational
The objective of this post marketing observational registry is to evaluate clinical outcomes (safety and performance) in an all-comers population with coronary artery disease (CAD) treated with the Polymer Free Sirolimus Eluting Coronary Stent Vivo ISAR and planned for an abbreviated (≤ 3 months) dual antiplatelet therapy (DAPT) regimen.
This study is a prospective, observational, multi-country, multi-Centre, single-arm registry designed to evaluate the clinical safety and performance of VIVO ISAR, Polymer Free Sirolimus Eluting Coronary Stent System. The study population is made up of subjects who have undergone PCI using VIVO ISAR and are receiving standard of care short DAPT treatment (≤ 3 months) . Subjects will be screened by site teams and offered the opportunity to participate in the registry after their procedure. Rationale for this study is to evaluate clinical outcomes and collect data of the Polymer Free Sirolimus Eluting Coronary Stent in real world CAD patients with follow-up at 1 month, 3 months and 12 months.
All medications and procedures to be used/ performed in this registry are commonly used/performed for clinical indications as part of standard of care and have well-defined safety profiles.
The study does not influence the choice of device utilized nor does it alter the routine standard of care. After a patient has been treated with the Vivo ISAR, informed consent will be requested and the eligible patient will be registered in the study.
Baseline data will be completed using medical notes. All recruited subjects will then be followed as per routine practice together with telephonic follow-up at 30 days, 3 months and 12 months from the baseline PCI procedure date.
The 30 day, 3 months and 12 month telephonic follow up will consist of a verbally report of the DAPT anticoagulation medications continued, about any lab assessments that might have happened, recording of any adverse events, and any interventional treatment that has occurred since previous contact.
4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →This is the only study on the registry with Translumina Therapeutics Pvt Ltd. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
A real-world population undergoing percutaneous coronary intervention with VIVO-ISAR (Polymer Free Sirolimus Eluting Coronary Stent) and intended for treatment with ≤ 3 months of DAPT
Exclusion Criteria:
Ischemic endpoint
Cardiovascular death, myocardial infarction (not clearly attributable to a non-target vessel), definite or probable stent thrombosis or urgent target lesion revascularization (TLR).
Time frame: 12 months
Bleeding endpoint
bleeding defined as Bleeding Academic Research Consortium (BARC) class 3 or higher
Time frame: 12 months
All-cause mortality
Mortality
Time frame: 12 months
Cardiovascular death
* Any death due to proximate cardiac cause (e.g., myocardial infarction, low-output failure, fatal arrhythmia). * Unwitnessed death and death of unknown cause. * All procedure-related deaths (including those related to concomitant treatment).
Time frame: 12 months
Myocardial infarction (MI)
Myocardial Infarction (including periprocedural myocardial infarction) as defined per the Fourth Universal Definition of Myocardial Infarction: "Detection of a rise and/or fall of cardiac troponin (cTn) with at least one value above the 99th percentile and with at least one of the following: 1. Symptoms of acute myocardial ischemia; 2. New ischemic electrocardiographic (ECG) changes; 3. Development of pathological Q waves; 4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology; 5. Identification of a coronary thrombus by angiography including intracoronary imaging or by autopsy."
Time frame: 12 months
Stroke
caused either by a clot obstructing the flow of blood to the brain (called an ischemic stroke) or by a blood vessel rupturing and preventing blood flow to the brain (called a hemorrhagic stroke)
Time frame: 12 months
Stent thrombosis (definite/probable)
Definite Stent Thrombosis: Angiographic confirmation of stent thrombosis: * The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent and presence of at least one of the following criteria within a 48-hour time window: * Acute onset of ischemic symptoms at rest * New ischemic ECG changes that suggest acute ischemia * Typical rise and fall in cardiac biomarkers b) Probable Stent Thrombosis Clinical definition of probable stent thrombosis is considered to have occurred after intracoronary stenting in the following cases: * Any unexplained death within the first 30 days. * Irrespective of the time after the index procedure, any MI that is related to documented ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause.
Time frame: 12 months
Target Lesion Revascularisation (TLR) - Ischemia driven (ID)
A TLR is considered ischemia-driven if angiography at follow-up shows a percent diameter stenosis ≥50% and if one of the following occurs: * Positive history of recurrent angina pectoris, presumably related to the target vessel. * Objective signs of ischemia at rest (ECG changes) or during exercise test (or equivalent), presumably related to the target vessel. * Abnormal results of any invasive functional diagnostic test (e.g., Doppler flow velocity reserve, fractional flow reserve). * A target lesion revascularisation (TLR) or target vessel revascularisation (TVR) with a diameter stenosis ≥70% even in the absence of the above-mentioned ischemic signs or symptoms TLR events which do not meet the criteria for ID-TLR are considered non-ID TLR events
Time frame: 12 months
Urgent TLR
Acute condition post index procedure where urgent revascularization of the target lesion is necessary
Time frame: 12 months
Target vessel revascularisation (TVR)
repeat percutaneous intervention or surgical bypass of any segment of a target vessel.
Time frame: 12 months
BARC class 2 bleeding
any overt, actionable sign of hemorrhage
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.